KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBIT (2016 - 2025)

Historic EBIT for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $300.0 million.

  • Teva Pharmaceutical Industries' EBIT rose 113448.28% to $300.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 81155.12%. This contributed to the annual value of $2.2 billion for FY2025, which is 81188.12% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EBIT of $300.0 million as of Q4 2025, which was up 113448.28% from $882.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EBIT ranged from a high of $882.0 million in Q3 2025 and a low of -$967.0 million during Q2 2022
  • For the 5-year period, Teva Pharmaceutical Industries' EBIT averaged around $90.4 million, with its median value being $189.0 million (2021).
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 157692.31% in 2024, then surged by 920000.0% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EBIT stood at $78.0 million in 2021, then crashed by 1305.13% to -$940.0 million in 2022, then surged by 180.43% to $756.0 million in 2023, then tumbled by 103.84% to -$29.0 million in 2024, then surged by 1134.48% to $300.0 million in 2025.
  • Its EBIT stands at $300.0 million for Q4 2025, versus $882.0 million for Q3 2025 and $455.0 million for Q2 2025.